Last checked at 29 Jun 2015 07:00
29 June 2015
ValiRx Plc
("ValiRx" or the "Company")
Grant of options
ValiRx Plc (AIM: VAL), the AIM-quoted life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, announces that on 26 June 2015, it granted 1,221,560 options over ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") to certain employees and directors of the Company, as set out in the table below.
Name of director | Number of shares held | % of issued share capital | Number of existing options
| Number of new options granted
| Total options now held | Options held as % of issued share capital |
Satu Vainikka | 224,909 | 0.75% | 472,000 | 222,000 | 694.000 | 2.3% |
George Morris | 188,287 | 0.62% | 406,000 | 191,000 | 597,000 | 2.0% |
| Gerry Desler | 141,875 | 0.47% | 404,240 | 189,760 | 594,000 | 2.0% |
Kevin Alexander | 104,278 | 0.34% | 371,200 | 173,800 | 545,000 | 1.8% |
Oliver de Giorgio-Miller | 59,555 | 0.2% | 344,000 | 211,000 | 555,000 | 1.8% |
Seppo Makinen | 10,187
| 0.03% | 224,000 | 105,000 | 329,000 | 1.1% |
Total Directors | 729,091 | 2.41% | 2,221,440 | 1,092,560 | 3,314,000 | 11% |
Other employees | Nil | Nil | 350,400 | 129,000 | 479,400 | 1.6% |
Total | 729,091 | 2.41% | 2,571,840 | 1,221,560 | 3,793,400 | 12.6% |
The new options were granted under the Company's stock option plan and have an exercise price of 51 pence. The new options are exercisable from 26 June 2015 until 25 June 2025.
Following the grant of the new options, the total number of Ordinary Shares under option held by directors, which could be issued, is 3,314,000 Ordinary Shares, representing approximately 11 per cent. of the current issued share capital of the Company.
In addition, a further 129,000 options have been granted to employees of the Company at an exercise price of 51 pence which are exercisable until 25 June 2025.
The issued share capital of the Company comprises 30,177,214 ordinary shares of 0.1 pence each.
For more information, please contact:
ValiRx plc | Tel: +44 (0)20 3008 4416 |
Dr Satu Vainikka | www.ValiRx.com |
Cairn Financial Advisers LLP (Nominated Adviser) | Tel: +44 (0)20 7148 7900 |
Liam Murray / Avi Robinson | |
Northland Capital Partners (Broker) | Tel: +44 (0) 20 7382 1100 |
Patrick Claridge / David Hignell John Howes / Abigail Wayne (Broking) | |
Peckwater PR | Tel: +44 (0)7879 458 364 |
Tarquin Edwards | tarquin.edwards@peckwaterpr.co.uk |
Notes for Editors
ValiRx Plc
ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.
The Company listed on AIM in October 2006 and is creating a portfolio of innovative products through investment in specific development projects. It actively manages projects within this portfolio as a trading company and is not an investment vehicle. The ValiRx business model spreads the risks of life science technology developments by minimising financial exposure and running a set of projects to defined commercial endpoints. This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.
The Company operates through the following divisional companies:
1. ValiFinn is the biomarkers and diagnostic development division
2. ValiPharma is the therapeutics division with two embedded technologies primarily directed at the treatment of cancers.